A new treatment for coronary atherosclerosis that combines a PCSK9 inhibitor with statin therapy has lowered cholesterol levels in high-risk patients to unprecedented levels marking the start of a new era in lipid lowering management say Australian and US researchers. Presenting the findings of the GLASGOV trial at the American Heart Association’s scientific meeting in ...
Unprecedented lipid lowering seen with PCSK9 inhibitor plus statin: GLASGOV
By Sunalie Silva
25 Nov 2016